Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck, Eisai Get CHMP Backing for Lenvima-Keytruda Combo in Two Cancers

10/15/2021 | 08:07am EST

By Colin Kellaher

Merck & Co. and Eisai Co. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of the combination of Eisai's Lenvima and Merck's Keytruda in two new cancer indications.

Merck, based in Kenilworth, N.J., and Tokyo-based Eisai said the CHMP recommended approval of the combination as a first-line treatment of adults with advanced renal cell carcinoma.

The committee also backed the combination for adults with advanced or recurrent endometrial carcinoma who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and aren't candidates for curative surgery or radiation advanced endometrial carcinoma.

The European Commission, which generally follows the CHMP's advice, will now review the recommendations, with decisions expected by the end of the year.

Eisai and Merck in March 2018 formed a collaboration to jointly develop, manufacture and commercialize Lenvima as monotherapy and in combination with Merck's blockbuster cancer drug Keytruda.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

10-15-21 0806ET

Stocks mentioned in the article
ChangeLast1st jan.
EISAI CO., LTD. -0.54% 7155 End-of-day quote.-2.94%
MERCK & CO., INC. -3.79% 79.16 Delayed Quote.-3.23%
All news about MERCK & CO., INC.
10:06aNew Analysis Shows Merck COVID-19 Pill Molnupiravir Less Effective Than Previously Repo..
MT
08:51aMerck & Co. Says Molnupiravir Cuts Risk of Severe COVID-19 Based on Trial Data
MT
07:41aMerck, Ridgeback Biotherapeutics' Molnupiravir Drug Reduced Risk of Severe COVID-19 Bas..
MT
06:46aMerck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Mo..
BU
05:56aUK To Test Merck & Co.'s COVID-19 Pill In National Study
MT
03:46aPfizer, Merck Reportedly Agree to License Production of Respective Experimental COVID-1..
MT
02:07aPfizer, Merck & Co. Set to Allow Vietnamese Companies to Produce COVID-19 Pill
MT
11/24Truist Securities Adjusts Merck's Price Target to $95 From $92, Reiterates Buy Rating
MT
11/24Merck to Present at the 4th Annual Evercore ISI HealthCONx Conference
BU
11/24Gilead Sciences, Merck Pause Phase 2 HIV Trial
MT
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 48 600 M - -
Net income 2021 13 638 M - -
Net Debt 2021 20 562 M - -
P/E ratio 2021 16,3x
Yield 2021 3,28%
Capitalization 200 B 200 B -
EV / Sales 2021 4,54x
EV / Sales 2022 3,78x
Nbr of Employees 73 500
Free-Float 70,5%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 79,16 $
Average target price 96,70 $
Spread / Average Target 22,2%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-3.23%207 835
JOHNSON & JOHNSON1.82%421 847
ROCHE HOLDING AG17.17%334 769
PFIZER, INC.38.25%285 639
NOVO NORDISK A/S68.76%247 704
ELI LILLY AND COMPANY55.18%237 527